Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
25,918.50
(
-0.14%
)
Dow Jones
49,442.56
(
-0.01%
)
Brent Oil
91.42
(
0.82%
)
Bitcoin
75,761.56
(
-0.17%
)
News Focus
News Focus
Post# of 257431
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 189283

Monday, 03/30/2015 3:25:10 PM

Monday, March 30, 2015 3:25:10 PM

Post# of 257431
(OCRX)—It’s an enigma that HTPX wanted to run a phase-3 Ravicti trial in HE insofar as such a label expansion would have compromised the sky-high orphan-drug pricing for Ravicti in UCDs. Now that HZNP has formally dropped the idea (#msg-112229035), we may never know the rationale for conducting such a trial.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today